Today, a Director at Xoma Corp (XOMA), Denman Van-Ness, sold shares of XOMA for $1,911.
Following Denman Van-Ness’ last XOMA Sell transaction on December 21, 2018, the stock climbed by 3.3%.
See today’s analyst top recommended stocks >>
Based on Xoma Corp’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $8.13 million and quarterly net profit of $1.88 million. In comparison, last year the company earned revenue of $463K and had a GAAP net loss of $3.81 million. Currently, Xoma Corp has an average volume of 62.18K.
Based on 3 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $27.50, reflecting a 85.6% upside.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
XOMA Corp. engages in the discovery and development of innovative therapeutics derived from platform of antibody technologies. Its products includes X358, X213, X129, and gevokizumab. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Emeryville, CA.
